Đăng xuất
Avodart treats and prevents
progression of benign prostatic hyperplasia (BPH) through alleviating symptoms,
reducing prostate size (volume), improving urinary flow rate and reducing the
risk of acute urinary retention (AUR) and the need for BPH‑related surgery.
Avodart in
combination with the alpha‑blocker tamsulosin, treats and prevents progression of benign
prostatic hyperplasia (BPH) by reducing prostate size, alleviating symptoms,
improving urinary flow and
reducing the risk of acute urinary retention (AUR) and the need for BPH‑related
surgery (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
